未知机构：中泰医药脑机动态定期更新近期部分重要进展1赵继宗-20260204

Summary of Key Points from Conference Call Records Industry Overview - The conference call focuses on the brain-computer interface (BCI) industry, highlighting recent advancements and developments in the field of medical technology related to brain-machine interfaces and rehabilitation robotics. Core Insights and Arguments 1. The release of the "Clinical Application Path Management Expert Consensus for Implantable Brain-Computer Interfaces (2026 Edition)" led by Academician Zhao Jizong aims to promote the scientific, safe, and orderly development of iBCI clinical translation [1] 2. The Ministry of Civil Affairs issued guidelines to advance technological innovation in civil affairs, emphasizing the application of humanoid robots, brain-computer interfaces, and artificial intelligence in various areas such as disability prevention, elderly care, and rehabilitation [1][2] 3. Neuralink announced that its first brain-computer interface product, "Telepathy," has enrolled 21 patients in clinical trials [1] 4. Qiangnao Technology launched a medical-grade product "Zhuanzhuo Xin" for children with ADHD, which consists of rehabilitation training software and a single-channel EEG collector, both of which have received Class II medical device registration from the National Medical Products Administration [1] 5. Fourier, an early player in the rehabilitation robotics industry, plans to introduce brain-computer interface solutions integrated with embodied intelligence for rehabilitation [1] 6. Fudan University and Huashan Hospital's neurosurgery department released clinical trial data on the "UltraBrainPad," a domestically developed ultrasound diagnostic and therapeutic device that opens the blood-brain barrier for glioblastoma patients, significantly increasing drug concentration in the brain [2] 7. Ybrain is recruiting former executives from Samsung Electronics and VUNO to promote a non-oral antidepressant based on tDCS and EEG technology, aiming to create an AI mental health ecosystem [2] 8. Neofect, a South Korean digital healthcare company, announced a collaboration with the HanDe Consortium to commercialize brain-computer interfaces, focusing on developing a brain-controlled rehabilitation robot system for stroke patients over a 36-month period [2] Additional Important Content - Future attention is recommended on the release of the 14th Five-Year Plan post the Two Sessions, upcoming approvals for invasive products, IPO filings from brain-machine companies, and clinical data releases from leading companies [2] - Investment suggestions include focusing on companies such as Aipeng Medical, Xiangyu Medical, Innovation Medical, Meihao Medical, Kefu Medical, Mailande, Weisi Medical, Sanbo Brain Science, Yanshan Technology, Chengyitong, and Lepu Medical, as well as potential IPO candidates like Qiangnao Technology and Borui Kang [2] - Risk factors highlighted include policy changes and the risk of commercialization of products or services not meeting expectations [3]